Physician profile
Jacklyn Osborn
NPI 1871209098
$2,178.77
in general payments reported to CMS, 2019-2025
14 companies · $697 in 2025
The $697 reported for 2025 was more than what 82% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $82.02 · 2023: $606 · 2024: $794 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,096.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $435.77 | 2023-2025 | Verquvo |
| Novo Nordisk INC | $369.56 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $292.55 | 2023-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.49 | 2023-2025 | Jardiance |
| Pfizer INC. | $169.23 | 2023-2025 | |
| Inspire Medical Systems, INC. | $146.42 | 2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $121.18 | 2024-2025 | |
| Scpharmaceuticals INC. | $115.62 | 2023-2024 | |
| Amgen INC. | $115.37 | 2024-2025 | Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $82.66 | 2023-2024 | |
| Lexicon Pharmaceuticals, INC. | $45.87 | 2023 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $45.56 | 2025 | Lifevest |
| Impulse Dynamics (USA) INC. | $23.28 | 2023 | Optimizer |
| Alnylam Pharmaceuticals INC. | $20.21 | 2025 | Amvuttra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacklyn Osborn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.